<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419913</url>
  </required_header>
  <id_info>
    <org_study_id>CHR2006 1.0</org_study_id>
    <nct_id>NCT00419913</nct_id>
  </id_info>
  <brief_title>A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF)</brief_title>
  <official_title>A Randomized Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) Treatment for Two Months Before Starting Ovulation Induction for in Vitro Fertilization (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Human Reproduction</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Reproductive Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Human Reproduction</source>
  <brief_summary>
    <textblock>
      Our long term goal is to elucidate the role of DHEA on follicular dynamics in the human ovary&#xD;
      and to better understand the interaction of DHEA supplementation with other treatments for&#xD;
      ovulation induction, especially among older reproductive age women.&#xD;
&#xD;
      The specific hypothesis behind the proposed research is that DHEA is a regulator of&#xD;
      follicular dynamics acting in the early pre-gonadotropin dependent stage of initial&#xD;
      primordial follicle recruitment and growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:&#xD;
&#xD;
      The ability of women to respond to ovulation inducing medications also called ovarian&#xD;
      reserve, declines with age. (Navot, Bergh et al. 1991; Scott, Leonardi et al. 1993; Toner and&#xD;
      Flood 1993 ; Scott and Hofmann 1995; Scott 1996; ASRM 2002) When attempting in-vitro&#xD;
      fertilization (IVF), older women produce few oocytes (Chuang, Chen et al. 2003; Orvieto,&#xD;
      Bar-Hava et al. 2004) and yield few normal embryos, even when exposed to maximal gonadotropin&#xD;
      stimulation.(Orvieto, Bar-Hava et al. 2004) As a result reproductive success for women over&#xD;
      40 years old is significantly reduced compared to younger women. Older ovaries have few&#xD;
      antral follicles, high rates of follicular degeneration (atresia)(Faddy 2000) and increased&#xD;
      &quot;resistance&quot; to ovulation induction.(Filicori 1999; Chuang, Chen et al. 2003; Kupesic, Kurjak&#xD;
      et al. 2003) A delay in onset of atresia could salvage follicles for later ovulation.&#xD;
&#xD;
      Our long term goal is to elucidate the role of DHEA on follicular dynamics in the human ovary&#xD;
      and to better understand the interaction of DHEA supplementation with other treatments for&#xD;
      ovulation induction, especially among older reproductive age women.&#xD;
&#xD;
      The specific hypothesis behind the proposed research is that DHEA is a regulator of&#xD;
      follicular dynamics acting in the early pre-gonadotropin dependent stage of initial&#xD;
      primordial follicle recruitment and growth. That hypothesis is based on the following&#xD;
      observations. First, at physiological doses DHEA increases serum levels of the insulin-like&#xD;
      growth factor (IGF-l).(Casson, Santoro et al. 1998) DHEA is produced by the ovarian&#xD;
      theca,(Burger 2002) increased concentration of follicular DHEA is associated with increased&#xD;
      aromatase activity,(Franks, Mason et al. 2000) and DHEA is a prohormone that is converted in&#xD;
      peripheral tissues to estrogens.(Haning, Hackett et al. 1993) Second, DHEA exposed rats&#xD;
      simulate polycystic ovary syndrome (PCO)(Roy, Mahesh et al. 1962) and have a higher&#xD;
      percentage of meiotically active oocytes and less evidence of atresia.(Anderson, Lee et al.&#xD;
      1997) Women chronically exposed to androgens can develop PCO-like ovaries.(Amirikia,&#xD;
      Savoy-Moore et al. 1986) Women with anovulatory PCO have less evidence of follicle&#xD;
      atresia.(Franks, Mason et al. 2000) Third, Casson et al (Casson, Lindsay et al. 2000) found a&#xD;
      small increase in follicle number and E2 response to ovulation induction after two months of&#xD;
      DHEA (80 mg/day) administration to five women, with proven ovarian resistance to stimulation.&#xD;
&#xD;
      Preliminary data Barad and Gleicher reported a patient with a history of severely decreased&#xD;
      ovarian reserve who dramatically increased her oocyte production over nine cycles of&#xD;
      treatment while taking DHEA and ovulation induction.(Barad and Gleicher 2005) The dramatic&#xD;
      increase in oocyte production seen in this patient did not occur until after four months of&#xD;
      DHEA treatment (75 mg/day). This treatment duration is in keeping with the interval required&#xD;
      for normal follicular initiation of recruitment and growth(Gougeon 1986) and raises that&#xD;
      possibility that the Casson et al. did not treat their subjects long enough to achieve&#xD;
      maximum effect. Our case report was followed by a case control study that showed increased&#xD;
      oocyte production and improved embryo quality among 25 DHEA treated patients, whose&#xD;
      pre-treatment cycle acted as control.(Barad and Gleicher 2005)&#xD;
&#xD;
      More recently we showed that DHEA treated patients with significant decreased ovarian reserve&#xD;
      have higher pregnancy rates compared to controls.(Barad, Brill et al. 2006)&#xD;
&#xD;
      Based on these observations the experimental focus of this project is on the interaction of&#xD;
      DHEA adjuvant treatment with gonadotropin treatment during ovulation induction. The specific&#xD;
      aims are designed to provide a comprehensive assessment of this effect.&#xD;
&#xD;
        1. DHEA treatment will increase pregnancy rates among women 40 to 45 years old.&#xD;
&#xD;
        2. DHEA treatment will increase antral follicle counts.&#xD;
&#xD;
        3. DHEA will lead to increased anti-mullerian (AMH) hormone levels.&#xD;
&#xD;
        4. DHEA treatment will increase mean and peak follicular phase estradiol.&#xD;
&#xD;
        5. DHEA treatment will increase the number of oocytes retrieved in IVF cycles compared to&#xD;
           placebo.&#xD;
&#xD;
      Research Plan:&#xD;
&#xD;
      Placebo controlled randomized trial of 2 months of DHEA pretreatment prior to ovulation&#xD;
      induction for IVF-ET.&#xD;
&#xD;
      Hypothesis 1:&#xD;
&#xD;
      Two months of DHEA pretreatment will improve the chance of pregnancy and lead to greater&#xD;
      oocyte and embryo yields relative to placebo treated control patients.&#xD;
&#xD;
      Hypothesis 2:&#xD;
&#xD;
      Embryos produced following 2 months of pretreatment with either DHEA alone OR with DHEA plus&#xD;
      supplemental FSH 150 units per day will result in embryos with better morphology&#xD;
&#xD;
      Hypothesis 3a-c:&#xD;
&#xD;
      Two months of DHEA pretreatment will result in: a) increased antral follicle counts,&#xD;
      increased AMH, b) increased mean and peak estradiol and c) increased oocyte production&#xD;
&#xD;
      Recruitment plan:&#xD;
&#xD;
        -  New patients presenting for treatment.&#xD;
&#xD;
        -  Possible print, magazine or Radio advertisement&#xD;
&#xD;
      References:&#xD;
&#xD;
      Amirikia, H., R. T. Savoy-Moore, et al. (1986). &quot;The effects of long-term androgen treatment&#xD;
      on the ovary.&quot; Fertil Steril 45(2): 202-8.&#xD;
&#xD;
      Anderson, E., G. Y. Lee, et al. (1997). &quot;Polycystic ovarian condition in the&#xD;
      dehydroepiandrosterone-treated rat model: hyperandrogenism and the resumption of meiosis are&#xD;
      major initial events associated with cystogenesis of antral follicles.&quot; Anat Rec 249(1):&#xD;
      44-53.&#xD;
&#xD;
      ASRM (2002). &quot;Aging and infertility in women: a committee opinion.&quot; Fertil Steril 78(1):&#xD;
      215-9.&#xD;
&#xD;
      Barad, D., H. Brill, et al. (2006). &quot;Dehydroepiandrosterone (DHEA) Increases Pregnancy Rates&#xD;
      in Women with Diminished Ovarian Reserve:&#xD;
&#xD;
      A Case Controlled Study.&quot; Submitted for Publication. Barad, D. and N. Gleicher (2005).&#xD;
      &quot;Effect of dehydroepiandrosterone (DHEA) on oocyte and embryo yields, embryo grade and cell&#xD;
      number in IVF.&quot; Human Reproduction In Press.&#xD;
&#xD;
      Barad, D. and N. Gleicher (2005). &quot;Increased Oocyte Production after Treatment with&#xD;
      Dehydroepiandrosterone.&quot; Fertil Steril 84(3): 756.&#xD;
&#xD;
      Burger, H. G. (2002). &quot;Androgen production in women.&quot; Fertil Steril 77 Suppl 4: S3-5.&#xD;
&#xD;
      Casson, P. R., M. S. Lindsay, et al. (2000). &quot;Dehydroepiandrosterone supplementation augments&#xD;
      ovarian stimulation in poor responders: a case series.&quot; Hum Reprod 15(10): 2129-32.&#xD;
&#xD;
      Casson, P. R., N. Santoro, et al. (1998). &quot;Postmenopausal dehydroepiandrosterone&#xD;
      administration increases free insulin-like growth factor-I and decreases high-density&#xD;
      lipoprotein: a six-month trial.&quot; Fertil Steril 70(1): 107-10.&#xD;
&#xD;
      Chuang, C. C., C. D. Chen, et al. (2003). &quot;Age is a better predictor of pregnancy potential&#xD;
      than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization.&quot;&#xD;
      Fertil Steril 79(1): 63-8.&#xD;
&#xD;
      Faddy, M. J. (2000). &quot;Follicle dynamics during ovarian ageing.&quot; Mol Cell Endocrinol 163(1-2):&#xD;
      43-8.&#xD;
&#xD;
      Filicori, M. (1999). &quot;The role of luteinizing hormone in folliculogenesis and ovulation&#xD;
      induction.&quot; Fertil Steril 71(3): 405-14.&#xD;
&#xD;
      Franks, S., H. Mason, et al. (2000). &quot;Follicular dynamics in the polycystic ovary syndrome.&quot;&#xD;
      Mol Cell Endocrinol 163(1-2): 49-52.&#xD;
&#xD;
      Gougeon, A. (1986). &quot;Dynamics of follicular growth in the human: a model from preliminary&#xD;
      results.&quot; Hum Reprod 1(2): 81-7.&#xD;
&#xD;
      Haning, R. V., Jr., R. J. Hackett, et al. (1993). &quot;Plasma dehydroepiandrosterone sulfate&#xD;
      serves as a prehormone for 48% of follicular fluid testosterone during treatment with&#xD;
      menotropins.&quot; J Clin Endocrinol Metab 76(5): 1301-7.&#xD;
&#xD;
      Kupesic, S., A. Kurjak, et al. (2003). &quot;Three-dimensional ultrasonographic ovarian&#xD;
      measurements and in vitro fertilization outcome are related to age.&quot; Fertil Steril 79(1):&#xD;
      190-7.&#xD;
&#xD;
      Navot, D., P. A. Bergh, et al. (1991). &quot;Poor oocyte quality rather than implantation failure&#xD;
      as a cause of age-related decline in female fertility.&quot; Lancet 337(8754): 1375-7.&#xD;
&#xD;
      Orvieto, R., I. Bar-Hava, et al. (2004). &quot;Results of in vitro fertilization cycles in women&#xD;
      aged 43-45 years.&quot; Gynecol Endocrinol 18(2): 75-8.&#xD;
&#xD;
      Roy, S., V. Mahesh, et al. (1962). &quot;The effect of dehydroepiandrosterone and&#xD;
      D4-androstenedione on the reproductive organs of female rats: Production of cystic changes in&#xD;
      the ovary.&quot; Nature 196: 42-43.&#xD;
&#xD;
      Scott, R. T., Jr. (1996). &quot;Evaluation and treatment of low responders.&quot; Semin Reprod&#xD;
      Endocrinol 14(4): 317-37.&#xD;
&#xD;
      Scott, R. T., Jr. and G. E. Hofmann (1995). &quot;Prognostic assessment of ovarian reserve.&quot;&#xD;
      Fertil Steril 63(1): 1-11.&#xD;
&#xD;
      Scott, R. T., M. R. Leonardi, et al. (1993). &quot;A prospective evaluation of clomiphene citrate&#xD;
      challenge test screening of the general infertility population.&quot; Obstet Gynecol 82(4 Pt 1):&#xD;
      539-44.&#xD;
&#xD;
      Toner, J. P. and J. T. Flood (1993). &quot;Fertility after the age of 40.&quot; Obstet Gynecol Clin&#xD;
      North Am 20(2): 261-72.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit sufficient participants.&#xD;
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Pregnancy per cycle of treatment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Embryos per cycle of treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oocytes per cycle of treatment</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Infertility</condition>
  <condition>Decreased Ovarian Reserve</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dehydroepiandrosterone (DHEA) 25mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dehydroepiandrosterone</intervention_name>
    <description>DHEA 25 mg tid</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over the age of 40 and less than 45 years old presenting for IVF treatment.&#xD;
&#xD;
          -  Willingness to sign informed consent for study randomization.&#xD;
&#xD;
          -  Willingness to participate in 2 months pre-IVF treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical condition that would contraindicate pregnancy, ovulation induction or general&#xD;
             anesthesia.&#xD;
&#xD;
          -  Family history of significant genetic disease, or factor V Leiden thrombophilia.&#xD;
&#xD;
          -  Inability to present for monitoring visits.&#xD;
&#xD;
          -  Inability to follow medication instruction.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Barad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Reproduction</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Reproduction</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute fur Reproduktionsmedzin und Endokrinologie</name>
      <address>
        <city>Bregenz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006 Nov;21(11):2845-9. Epub 2006 Sep 22.</citation>
    <PMID>16997936</PMID>
  </reference>
  <reference>
    <citation>Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005 Sep;84(3):756.</citation>
    <PMID>16169414</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>January 7, 2007</study_first_submitted>
  <study_first_submitted_qc>January 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. David H. Barad</name_title>
    <organization>Center for Human Reproduction</organization>
  </responsible_party>
  <keyword>Ovulation Induction</keyword>
  <keyword>In vitro Fertilization</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

